Luger SM, Wang VX, Rowe JM, Litzow MR, et al. Tipifarnib as maintenance therapy did not improve disease-free survival in patients with acute myelogenous leukemia at high risk of relapse: Results of the phase III randomized E2902 trial. Leuk Res 2021;111:106736.
PMID: 34773794